The answer
in the technology

BUTYROSE® LSC® Microcaps

Dietary food intended for special medical purposes based on sodium butyrate LSC® Microcaps, EU patent n.2352386 for slow release in the colon / rectum.For the diet of people suffering from colon diseases with altered trophism of the intestinal mucosa. Ingredients: Microencapsulated sodium butyrate (certified sustainable hydrogenated palm oil *, sodium butyrate, bulking agent: E 516, flavorings, glazing agent: E 477), vegetarian capsule (glazing agent: E 464, color E 171 **). Without gluten, lactose, sugars, yeasts and preservatives.How to use: 2-3 capsules a day close to meals, in case of difficulty swallowing it is possible to open the capsule and take its contents by dispersing it in drinks or semi-solid foods.There are no time limits to administration. Pack of 30 or 15 slow-release capsules of 600 mg containing 500 mg of microencapsulated sodium butyrate.

  * RSPO License no. 9-1708-16-100-00

** the dye is present exclusively in the outer operculum



To best perform its functions – including promoting metabolic health with an eutrophic effect on the colon mucosa and bioregulating the intestinal flora – (see scientific papers), it is preferable that butyric acid is in the form linked to sodium due to its high lipophilicity and cell exchange capacity.

Sodium butyrate is a very active molecule but with a high degree of dissociation (pKa 4.82), which in the absence of adequate protection would not reach the intestine, in particular the colon / rectum.

This is why Butyrose® contains Sodium Butyrate LSC® microcaps: thanks to its patented formula (EU n.2352386), sodium butyrate is incorporated into a lipophilic microcapsule with LSC® -Lipophilic Spray Cooling- barrier effect technology, which it guarantees stability to the sodium-butyrate bond, a wide active surface and an extended diffusion capacity in the intestine, especially in the colon, where the bacterial concentration is greater.


Diarrhea, abdominal pain and general malaise – people with these symptoms may be in a condition in which intestinal inflammation is underway and the flora is altered.

In fact, the intestine is colonized by a rich population of bacteria that make up the so-called “intestinal flora” or “microbiota”. The alterations of the microbiota are: Eubiosis and Dysbiosis.

The first is the physiological condition characterized by a correct balance between the bacterial species that naturally colonize the intestine. The second refers to a condition of altered balance between the bacterial species that normally colonize the intestine.